Light Mode
$0.0367 ↓ -0.4533 (-92.51%) Trading Down from the previous close of $0.4900, $0.4533 below the day’s high of $0.4900
-0.10 (-17.65%) / 6M
Momentum, market sentiment, and recent alerts
ORGS reads n/a: price sits below both the 20- and 200-day averages, the 12-month move is -46.2%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies and services in the cell and gene therapy industry. It operates through the following segments: Octomera and Therapies. The Octomera segment refers to the point-of-care services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.